Patients with Crohn's disease (CD) are at risk of surgery due to refractory or penetrating disease, which may result in short bowel syndrome (SBS) that requires parenteral nutrition (PN). Teduglutide is a GLP2 analogue that has been approved for the treatment of SBS although there has been limited evidence for its use in CD patients. There is a theoretical risk of exacerbating mucosal inflammation with teduglutide due to intestinotrophic effects of GLP2. Aims: To assess the safety and efficacy of combined biologic therapy and teduglutide in patients with active CD and SBS. Methods: We present two cases of CD patients with active inflammation and SBS treated with combination biologic therapy and teduglutide. Results: The first case is a 38-year-old male with ileocolic stricturing CD, who previously failed methotrexate, azathioprine, infliximab and adalimumab. He underwent multiple small bowel and ileocolic resections resulting in SBS and was initiated on 7-day home parenteral nutrition (PN) in 2011 for SBS. Teduglutide was commenced in January 2017 and he was able to wean completely off PN within seven months. Ileocolic anastomotic inflammation was treated with ustekinumab in July 2017, and both treatments have been maintained for 14 months without any adverse events.
